SUPERNUS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
SUPN$27.62+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share amounts)
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $75,054 | $93,120 |
| Marketable securities | 179,820 | 368,214 |
| Accounts receivable, net | 144,155 | 165,497 |
| Inventories, net | 77,408 | 91,541 |
| Prepaid expenses and other current assets | 16,676 | 15,779 |
| Total current assets | 493,113 | 734,151 |
| Long term marketable securities | 16,617 | 93,896 |
| Property and equipment, net | 13,530 | 15,173 |
| Intangible assets, net | 599,889 | 702,463 |
| Goodwill | 117,019 | 117,019 |
| Other assets | 37,505 | 39,806 |
| Total assets | $1,277,673 | $1,702,508 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $79,569 | $96,342 |
| Accrued product returns and rebates | 154,274 | 151,665 |
| Contingent consideration, current portion | 52,070 | 21,120 |
| Convertible notes, net | — | 401,968 |
| Other current liabilities | 4,283 | 16,863 |
| Total current liabilities | 290,196 | 687,958 |
| Contingent consideration, long term | 1,380 | 33,847 |
| Operating lease liabilities, long term | 33,196 | 35,998 |
| Deferred income tax liabilities, net | 24,963 | 49,809 |
| Other liabilities | 6,422 | 8,692 |
| Total liabilities | 356,157 | 816,304 |
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 54,723,356 and 54,253,796 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 55 | 54 |
| Additional paid-in capital | 439,493 | 408,115 |
| Accumulated other comprehensive (loss) earnings, net of tax | (593) | (3,210) |
| Retained earnings | 482,561 | 481,245 |
| Total stockholders’ equity | 921,516 | 886,204 |
| Total liabilities and stockholders’ equity | $1,277,673 | $1,702,508 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.